Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184614 | 0.86 | NOTUM (0.67) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL111187 | 0.86 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL654773 | 0.86 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| Methyl 3,5-Dibromobenzoate SCHEMBL2408987 | 0.86 | NOTUM (0.67) | NOTUMCA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL9494959 | 0.84 | CA1 (0.56) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL111186 | 0.84 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16684548 | 0.82 | NOTUM (0.48) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL2725407 | 0.81 | NPC1 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29944879 | 0.81 | NPC1 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14783973 | 0.81 | NOTUM (0.57) | NOTUMCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| CN-119552166-A | PARP1/CDK6 double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1360173-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002059080-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | NOTUM 628/4885CA12 3755/4885CA1 4718/4885 |
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | NOTUM 657/4885CA12 1383/4885CA1 1976/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | NOTUM 2035/4885CA12 4281/4885CA1 4371/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | NOTUM 628/4885CA12 3755/4885CA1 4718/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | NOTUM 1414/4885CA12 3919/4885CA1 2419/4885 |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | NOTUM 657/4885CA12 1383/4885CA1 1976/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | NOTUM 4089/4885CA12 4037/4885CA1 3576/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | NOTUM 4651/4885CA12 4345/4885CA1 3386/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | NOTUM 4384/4885CA12 4753/4885CA1 4568/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | NOTUM 3014/4885CA12 4808/4885CA1 4853/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | NOTUM 628/4885CA12 3755/4885CA1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.